Kenvue Inc. (KVUE)
Automate Your Wheel Strategy on KVUE
With Tiblio's Option Bot, you can configure your own wheel strategy including KVUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KVUE
- Rev/Share 7.8983
- Book/Share 5.5973
- PB 2.8031
- Debt/Equity 0.8149
- CurrentRatio 0.9776
- ROIC 0.0756
- MktCap 30110208300.0
- FreeCF/Share 0.8519
- PFCF 18.4386
- PE 21.2114
- Debt/Assets 0.3223
- DivYield 0.0524
- ROE 0.138
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | KVUE | Rothschild & Co Redburn | Neutral | Buy | -- | $22 | Sept. 26, 2025 |
| Initiation | KVUE | Redburn Atlantic | -- | Neutral | -- | $23.5 | April 10, 2025 |
| Initiation | KVUE | Evercore ISI | -- | In-line | -- | $25 | March 24, 2025 |
| Upgrade | KVUE | Piper Sandler | Neutral | Overweight | $21 | $26 | Jan. 6, 2025 |
| Downgrade | KVUE | Deutsche Bank | Buy | Hold | $25 | $24 | Dec. 12, 2024 |
| Downgrade | KVUE | RBC Capital Mkts | Outperform | Sector Perform | -- | $24 | Sept. 24, 2024 |
| Initiation | KVUE | Jefferies | -- | Buy | -- | $27 | Sept. 24, 2024 |
News
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
Published: October 03, 2025 by: WSJ
Sentiment: Neutral
In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.
Read More
Kenvue: This Too Shall Pass
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Positive
Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts for roughly $1 billion in sales and a fraction of Kenvue's total revenue. The current valuation implies an unrealistic 40%+ decline in Tylenol sales, which seems excessive given the actual business impact.
Read More
Trump links autism to Tylenol ingredient use during pregnancy — here's what to know
Published: September 24, 2025 by: CNBC Television
Sentiment: Neutral
The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol. CNBC's Angelica Peebles explains.
Read More
Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
Published: September 23, 2025 by: Investopedia
Sentiment: Neutral
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Read More
Trading meme stocks, gold, and crypto, Kenvue's stock rebounds
Published: September 23, 2025 by: Yahoo Finance
Sentiment: Positive
Opening Bid anchor Brian Sozzi breaks down the latest market news for September 23, 2025. Our panel looks at the latest moves in meme stocks Opendoor and Better Homes, weakness in the crypto market, and gold's continued climb to new highs.
Read More
Pharmaceutical Stock Bounces Off Record Lows
Published: September 23, 2025 by: Schaeffers Research
Sentiment: Positive
Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of acetaminophen -- the active ingredient of the company's Tylenol pain drug -- in pregnancy and autism.
Read More
Tylenol: Kenvue's Sobering Reality
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Negative
I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.
Read More
Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism
Published: September 23, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on the Trump administration's announcement linking acetaminophen taken during pregnancy to autism.
Read More
KVUE Rebounds Against Trump Admin, BA International Boost, AZO Earnings Miss
Published: September 23, 2025 by: Schwab Network
Sentiment: Neutral
Kenvue (KVUE) rallied Tuesday morning despite the Trump administration linking Tylenol to autism. Diane King Hall notes that analyst commentary may have helped the stock's upward trajectory.
Read More
Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
Published: September 23, 2025 by: Forbes
Sentiment: Positive
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
Read More
Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autism
Published: September 23, 2025 by: Forbes
Sentiment: Negative
23%. That's the estimated percentage of adults in the U.S.—roughly 52 million people—who consume a medicine with acetaminophen each week, according to the nonprofit Consumer Healthcare Products Association.
Read More
Kenvue bounces after Trump's Tylenol remarks spark sell-off
Published: September 23, 2025 by: Proactive Investors
Sentiment: Positive
After a bruising session on Monday, Kenvue Inc (NYSE:KVUE) shares staged a 6% rebound in premarket trade on Tuesday, clawing back much of the previous day's 7.5% drop. The rally came after President Donald Trump repeatedly told pregnant women to avoid Tylenol, reviving disputed claims of a link between the painkiller and autism.
Read More
Kenvue says Tylenol is safe, but stock hits record low ahead of Trump speech
Published: September 22, 2025 by: Market Watch
Sentiment: Negative
Kenvue's stock was heading for a record low as investors express concerns over what President Trump will say regarding the use of acetaminophen — the active ingredient in Tylenol — and the autism epidemic.
Read More
Top Stock Movers Now: Nvidia, Apple, Kenvue, and More
Published: September 22, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes climbed Monday afternoon, boosted by the tech sector as Nvidia (NVDA) announced a $100 billion investment in ChatGPT maker OpenAI to build out AI data centers.
Read More
Kenvue stock sinks to record low as Trump to reportedly link Tylenol use to autism
Published: September 22, 2025 by: Invezz
Sentiment: Negative
Shares of Kenvue, the consumer-health spinoff of Johnson & Johnson, tumbled 7.1% to a record low of $17.03 on Monday with the selloff coming ahead of US President Donald Trump's planned announcement that use of Tylenol — Kenvue's top-selling pain reliever — during pregnancy could contribute to autism risk, according to reports.
Read More
Canaccord Genuity's Anderson: Kenvue sell-off ‘unwarranted,' stock looks like a buying opportunity
Published: September 22, 2025 by: CNBC Television
Sentiment: Positive
Kenvue shares tumbled more than 7% after reports that the Trump administration may link Tylenol use during pregnancy to autism risk. Canaccord Genuity analyst Susan Anderson joins 'Money Movers' to share her outlooks on the stock.
Read More
Kenvue Shares Fall on Report That White House Plans to Link Tylenol to Autism Risk
Published: September 22, 2025 by: Investopedia
Sentiment: Neutral
Shares of Tylenol maker Kenvue (KVUE) are dropping in morning trading on a report that the White House is expected to make an announcement Monday linking pregnant women's use of the painkiller to increased risk of autism.
Read More
Kenvue takes a $1.4bn Tylenol hit
Published: September 22, 2025 by: Proactive Investors
Sentiment: Negative
Kenvue Inc (NYSE:KVUE) shares dropped 4% at the open on Monday, erasing about $1.4 billion in market value, after a report that Trump administration officials plan to warn pregnant women against taking Tylenol unless they have a fever. The Washington Post said the guidance will claim the active ingredient, acetaminophen, is linked to autism, citing unnamed sources.
Read More
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
Read More
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Published: September 12, 2025 by: Market Watch
Sentiment: Negative
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Read More
Dividend Kings: 2 Ideal Buys In 25 "Safer" Of 56 September Dogs
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Kings list now includes 56 stocks, but only a select few offer fair value and strong yields relative to share price. Five top-yielding Dividend Kings—UVV, CDUAF, NWN, UBSI, and KVUE—currently meet my ideal of annual dividends exceeding share price. Analyst targets suggest these top-yield Kings could deliver net gains of 16% to 75% by September 2026, with lower volatility than the market.
Read More
Tylenol maker's stock dips after report says RFK Jr.'s HHS plans to link the drug to autism
Published: September 08, 2025 by: Fast Company
Sentiment: Negative
The U.S. Department of Health and Human Services (HHS) is planning to release a report that will reportedly link autism and acetaminophen use in pregnancy, according to The Wall Street Journal. The department has confirmed a report is in the works, but has not revealed its conclusions.
Read More
Tylenol-maker shares sink after report says RFK's HHS will link to autism
Published: September 05, 2025 by: Fox Business
Sentiment: Negative
Shares in the the parent company of Tylenol-maker McNeil Consumer Healthcare sank after a report suggested Robert F. Kennedy Jr.'s HHS will name the drug as a potential cause of autism.
Read More
RFK Jr. Report Will Link Autism To Tylenol Use During Pregnancy, Report Says
Published: September 05, 2025 by: Forbes
Sentiment: Negative
A promised report from Health and Human Services Secretary Robert F. Kennedy Jr. will claim the use of the common painkiller Tylenol during pregnancy is a potential cause for autism, The Wall Street Journal reported, while the drug's maker maintains the drug's safety.
Read More
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy
Published: September 05, 2025 by: CNBC
Sentiment: Negative
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy
Read More
Kenvue Can't Be Written Off Yet
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Negative
Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board, new leadership, and new strategy suggest real change is on the way for a business where execution clearly is a concern.
Read More
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Kenvue, Inc. (NYSE:KVUE ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amit Banati - Chief Financial Officer Kirk L. Perry - Interim CEO & Director Sofya Tsinis - Head of Investor Relations Conference Call Participants Andrea Faria Teixeira - JPMorgan Chase & Co, Research Division Bonnie Lee Herzog - Goldman Sachs Group, Inc., Research Division Filippo Falorni - Citigroup Inc., Research Division Javier T.
Read More
Kenvue misses Q2 sales estimates, cuts 2025 profit forecast
Published: August 07, 2025 by: Proactive Investors
Sentiment: Negative
Kenvue Inc (NYSE:KVUE) reported second quarter sales below Wall Street expectations, while also downwardly revising its full-year profit forecast. The Neutrogena, Aveeno, Tylenol and Band-Aid owner reported net sales were down 4%, driven by weaker allergy and sun season demand in North America and shipment timing changes in China.
Read More
Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Should You Buy Kenvue Stock At $22?
Published: August 05, 2025 by: Forbes
Sentiment: Negative
Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental weaknesses that render the stock unattractive for new investors at this time.
Read More
About Kenvue Inc. (KVUE)
- IPO Date 2023-05-04
- Website https://www.kenvue.com
- Industry Household & Personal Products
- CEO Thibaut Mongon
- Employees 22000